Brief: Jasper Therapeutics Inc - Initial Data From Phase 1B/2A Beacon Study Expected In Mid-2024

Jasper Therapeutics

05/01/2024 13:52

Jan 5 (Reuters) - Jasper Therapeutics Inc  JSPR.O :
    * INITIAL DATA FROM PHASE 1B/2A BEACON STUDY IN CSU EXPECTED
IN
MID-2024
    * EU CLINICAL TRIALS AUTHORIZED FOR PHASE 1B/2A SPOTLIGHT
AND
BEACON STUDIES OF BRIQUILIMAB IN CINDU AND CSU, RESPECTIVELY
    * PATIENT ENROLLMENT IN PHASE 1B/2A SPOTLIGHT STUDY OF
BRIQUILIMAB
IN CINDU EXPECTED TO COMMENCE IN Q1 OF 2024
    * INITIAL DATA READOUT FROM STUDY OF BRIQUILIMAB IN CINDU
EXPECTED
IN SECOND HALF OF 2024

Source text for Eikon:  ID:nGNX3KMpd6 
Further company coverage:  JSPR.O 

 ((Reuters.Briefs@thomsonreuters.com;))